# Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD

> **NCT04968938** · PHASE2 · WITHDRAWN · sponsor: **Resilient Pharmaceuticals**

## Conditions studied

- Posttraumatic Stress Disorder

## Interventions

- **DRUG:** midomafetamine
- **BEHAVIORAL:** Therapy

## Key facts

- **NCT ID:** NCT04968938
- **Lead sponsor:** Resilient Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-08
- **Primary completion:** 2023-08
- **Final completion:** 2023-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor decided not to pursue the study. Study ended prior to study start.
- **Last updated:** 2024-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04968938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04968938, "Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04968938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*